Aktis Oncology Secures $175M Series B Funding with Backing from Industry Giants

Funding Amount:
Aktis Oncology has raised $175 million in its Series B funding round.

Industry Backing:
The funding round drew support from industry giants including Lilly, Bristol Myers Squibb (BMY), and Merck (MRK).

Purpose:
The funding will be used to develop a pipeline of new targeted alpha radiopharmaceuticals for treating a range of cancers.

Investment Interest:
The Series B round indicates significant investor interest in Aktis Oncology's approach to cancer treatment, aligning with broader trends in biotech funding.

Market Context:
This investment is part of a larger trend in biotech funding, with several companies securing substantial funding for innovative cancer treatments, such as Third Arc Bio and Tubulis.